Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02775786 · ClinicalTrials.gov registry record · NA

Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma

A NA study, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
47
Enrollment target

NCT02775786 is a NA study that has completed, run by Columbia University. The registered enrollment target is 47 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02775786, a NA study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
47 participants
Enrollment target

Study Summary

This is a prospective cohort study in participants with pancreatic adenocarcinoma who are undergoing surgical resection. Participants will have up to two magnetic resonance imaging (MRI) scans with and without intravenous contrast. The MRI will be performed using either an extracellular contrast agent or using a macromolecular contrast agent. These contrast agents are routinely used in body MRI and are on formulary at this institution. Parameters will be compared to histopathology measures of mean vascular density and grade of fibrosis, respectively. The purpose is to establish a standard protocol for future clinical trials of treatments that would use MRI parameters as quantitative markers of treatment effect.

Interventions

  • OTHER MRIs with and without intravenous contrast (up to 2)

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2013-11
Est. Completion 2021-02-10
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT02775786

The ClinicalTrials.gov registry entry for NCT02775786 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which MRIs with and without intravenous contrast (up to 2) is the first listed.

NCT02775786 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02775786 about?

NCT02775786 is a clinical study titled "Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma". This is a prospective cohort study in participants with pancreatic adenocarcinoma who are undergoing surgical resection. Participants will have up to two magnetic resonance imaging (MRI) scans with and without intravenous contrast. The MRI will be performed using either an extracellular contrast age...

What is the current status of trial NCT02775786?

This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2013-11. Estimated completion is 2021-02-10.

What interventions are being tested in trial NCT02775786?

The interventions under investigation include: MRIs with and without intravenous contrast (up to 2) (OTHER).

Who is sponsoring clinical trial NCT02775786?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.